THE PROSPECTS OF INOZITOL USING IN WOMEN WITH POLYCYSTIC OVARY SYNDROME (LITERATURE REWIEV)

Authors

  • M. S. Khmil I. Horbachevsky Ternopil State Medical University Medical Center "Clinic of Professor S. Khmil", Ternopil, Ukraine
  • A. S. Khmil-Doswald I. Horbachevsky Ternopil State Medical University
  • S. V. Khmil I. Horbachevsky Ternopil State Medical University Medical Center "Clinic of Professor S. Khmil", Ternopil, Ukraine
  • I. Ya. Pidhaina I. Horbachevsky Ternopil State Medical University

DOI:

https://doi.org/10.11603/1681-2786.2018.4.10035

Keywords:

Inositol, mio-inositol, D-chiro-inositol, pregravid preparation, polycystic ovary syndrome, assisted reproductive technologies, fertility, reproductive health, extracorporal fertilization, FT 500 Plus

Abstract

Purpose: to conduct the analysis of modern domestic and foreign literature of the influence of inositol in pregravid preparation in women with polycystic ovary syndrome.

Materials and methods. The research used bibliosemantic and analytical methods. During the study, 25 sources of modern domestic and foreign literature of inositol influence on the reproductive health of women with polycystic ovary syndrome were analyzed.

Results. The inositol deficiency in women with polycystic ovarian syndrome is associated with poor oocyte quality and a violation of folliculogenesis. High concentrations of inositol in the follicular fluid are associated with oocytes of high quality and the development of good quality embryos. Also found a significant positive correlation between the inositol concentrations and the division of fertilized eggs. Pregravid preparation for programs of assisted reproductive technologies, which included inositol containing drugs, made it possible to reduce the doses of recombinant FSH and the duration of stimulation of superovulation.

Patients receiving inositol experienced an increase in estradiol levels and recovery of ovulation. The use of inositol also contributed to the increase in high-density lipoprotein, lowering testosterone levels, and increased progesterone levels.

Conclusions. Polycystic ovarian syndrome is associated with endocrine infertility. Inositol is effective in pregravid preparation for women with polycystic ovary syndrome, affecting the recovery of metabolic disorders. It has a significant influence on the reproductive function of women (normalization of menstrual cycle regulation, recovery of ovulation). Positively affects to the results of assisted reproductive technologies programs (improves the quality of oocytes and embryos, increasing the frequency of pregnancy).

Author Biographies

M. S. Khmil, I. Horbachevsky Ternopil State Medical University Medical Center "Clinic of Professor S. Khmil", Ternopil, Ukraine

Assistant at the Department of Obstetrics and Gynecology №1 of I.Horbachevsky Ternopil State Medical University. Medical director of the medical Center «The Clinic of Professor Stefan Khmil»

A. S. Khmil-Doswald, I. Horbachevsky Ternopil State Medical University

post-graduate student of the Department of Obstetrics and Gynecology №1 of I.Horbachevsky Ternopil State Medical University

S. V. Khmil, I. Horbachevsky Ternopil State Medical University Medical Center "Clinic of Professor S. Khmil", Ternopil, Ukraine

Professor at the Department of Obstetrics and Gynecology №1 of I.Horbachevsky Ternopil State Medical University. Merited Figure of Science and Technology of Ukraine, Professor, Doctor of Medical Science, Director of the medical Center «The Clinic of Professor Stefan Khmil»

I. Ya. Pidhaina, I. Horbachevsky Ternopil State Medical University

is a 6th year student, of I.Horbachevsky Ternopil State Medical University

References

Gromova, O.A., Torshin, I.Yu., & Limanova, O.A. (2013). Perspektivy ispolzovaniya mio-inozitola u zhenshchin s polikistozom yaichnikov i insulinorezistentnostyu v programmakh pregravidarnoy podgotovki k ekstrakorporalnomu oplodotvoreniyu. Effektivnaya Farmakoterapiya. Akusherstvo i Ginekologiya – Efficient Pharmacotherapy. Obstetrics and Gynecology, 5 (54), 12-23 [in Russian].

Kalugina, L.V., & Yusko, T.I. (2018). Mio-inozitol: terapevticheskie vozmozhnosti i pregravidarnaya podgotovka pri sindrome polikistoznyih yaichnikov (obzor literatury) [Myo-inositol: therapeutic options and pregravid preparation in polycystic ovary syndrome (literature review)]. (2018). Reproduktyvna endokrynolohiia – Reproductive Endocrinology, 4 (42), 40-45 [in Russian].

Kapshuk, I.M., & Islamova, H.O. (2018). Osoblyvosti likuvannia syndromu polikistoznykh yaiechnykiv u zhinok z metabolichnym syndromom [Features of treatment of polycystic ovary syndrome in women with metabolic syndrome]. Endokrynna hinekolohiia – Endocrine Gynecology (13) [in Ukrainian].

Limanova, O.A., Gromova, O.A., Torshin, I.Yu., Gromov, A.N., & Grishina, T.R. (2013). Sistematicheskiy analiz molekulyarno-fiziologicheskih effektov mio-inozitola: dannye molekulyarnoy biologii, eksperimentalnoy i klinicheskoy meditsiny [Systemic analysis of molecular-physiological effects of myo-inositol: data from molecular biology, experimental and clinical medicine (2013). Effektivnaya farmakoterapiya – Effective Pharmacotherapy, (28), 4-12 [in Russian].

Tatarchuk, T.F., Ganzhiy, I.Yu., Pedachenko, N.Yu., & Kapshuk, I.M. (2013). Suchasni mozhlyvosti nehormonalnoho likuvannia syndromu polikistoznykh yaiechnykiv u zhinok z ozhyrinniam [Contemporary possibilities of non-hormonal treatment of polycystic ovary syndrome in obese women]. Reproduktyvna endokrynolohiia Reproductive Endocrinology, 5 (13), 19-21 [in Ukrainian].

Chernuha, G.E., Kaprina, E.K., & Naydukova, A.A. (2015). Novye vozmozhnosti korrektsii narusheniy funktsii reproduktivnoy sistemy pri sindrome polikistoznykh yaichnikov [New possibilities of correction of disorders of reproductive system function in polycystic ovary syndrome]. Meditsinskiy sovet – Medical Board (9), 34-38 [in Russian].

Benelli, E., Del Ghianda, S., & Di Cosmo, C. (2016). A combined therapy with myo-inositol and d-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. International Journal of Endocrinology. doi: 10.1155/2016/3204083.

Angik, R., Jajoo, S., & Hariharan, C. (2015). A comparative study of metabolic and hormonal effects of myo inositol versus metformin in women with Polycystic ovary syndrome: a randomized controlled trial. International Journal of Reproduction Contraception Obstetrics Gynecology, 4(1), 189-194.

Jyoti Nehra, Jyoti Kaushal, Savita Rani Singhal. (2017). A comparative study of myo inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women. IJPSR, 8 (4), 1664-1670.

Unfer, V., Nestler, J., & Kamenov, Z. (2016). Effects of inositol(s) in women with PCOS: a systematic review of randomized controlled trials. International Journal of Endocrinology. doi: 10.1155/2016/1849162.

Garg, D., & Tal, R. (2016). Inositol treatment and ART outcomes in women with PCOS. International Journal of Endocrinology. doi.org/10.1155/2016/1979654.

Genazzani, A. (2016). Inositol as putative integrative treatment for PCOS. Reproductive BioMedicine Online, 33 (6), 770-780.

Unfer, V., Facchinetti, F., & Orrù, B. (2017). Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections, (6), 647-658.

Santamaria, A., Di Benedetto, A., & Petrella, E. (2015). Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine, (19). doi.org/10.3109/14767058.2015.1121478.

D’Anna, R., Scilipoti, A., & Giordano, D. (2013). Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care, (36), 854-857.

D’Anna, R., Di Benedetto, A., & Scilipoti, A. (2015). Myo-inositol supplementation for prevention of gestational diabetes in obese pregnant women: a randomized controlled trial. Obstetrics and Gynecology, (126), 310-315.

Celentano, C., Matarrelli, B., & Mattei, P. (2016). Myo-inositol supplementation to prevent gestational diabetes mellitus. Current Diabetes Reports, 16 (30). doi: 10.1007/s11892-016-0726-6.

Caprio, F., D`Eufemia, M.D., & Trotta, C. (2015). Myo-inositol therapy for poor-responders during IVF: a prospective controlled observational trial. Journal of Ovarian Research, 8 (37).

Govindarajan, C., Pitchaipillai, C., & Shanmugasundaram, B. Myoinositol: a review of its use in patients with polycystic ovary syndrome. World Journal of Pharmacy and Pharmaceutical Sciences, 4 (6), 137-155.

Qin, J.Z., Pang, L.H., & Li, M.J. (2013). Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reproductive Biology and Endocrinology.

Bizzarri, M., Fuso, A., & Dinicola, S. (2016). Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert Opinion on Drug Metabolism and Toxicology, (12), 1181-1196.

Zheng, X., Liu, Z., & Zhang, Y. (2015). Relationship between myo-inositol supplementary and gestational diabetes mellitus: a meta-analysis. Medicine (Baltimo), 94 (42).

Inas, T., & Brigid, G. (2017). Metformin; a review of its history and future: from lilac to longevity. Pediatr. Diabetes, (18), 10-16.

Nas, K., Breyer, H., & Tűű, L. (2015). The role of tailored treatment on conception and pregnancy at patients with insulin resistance. Endocrine Abstracts. DOI: 10.1530/endoabs.37.EP189.

Hadjiconstantinou, M., Mani, H., & Patel, N. (2017). Understanding and supporting women with polycystic ovary syndrome: a qualitative study in an ethnically diverse UK. Endocrine Connections, (6), 323-330.

Downloads

Published

2019-04-19

How to Cite

Khmil, M. S., Khmil-Doswald, A. S., Khmil, S. V., & Pidhaina, I. Y. (2019). THE PROSPECTS OF INOZITOL USING IN WOMEN WITH POLYCYSTIC OVARY SYNDROME (LITERATURE REWIEV). Bulletin of Social Hygiene and Health Protection Organization of Ukraine, (4), 82–89. https://doi.org/10.11603/1681-2786.2018.4.10035

Issue

No. 4 (2018)

Section

The review of the scientific literature

License

Authors who publish in this journal agree to the following terms:

1. The authors reserve the right to authorship of the work and pass the journal right of first publication of this work is licensed under a Creative Commons Attribution License, which allows others to freely distribute the work published with reference to the authors of the original work and the first publication of this magazine.

 2. Authors are entitled to enter into a separate agreement on additional non-exclusive distribution of work in the form in which it was published in the magazine (eg work place in the electronic repository institution or publish monographs in part), provided that the reference to the first publication of this magazine.

3. Policy magazine allows and encourages authors placement on the Internet (eg, in storage facilities or on personal websites) manuscript of how to submit the manuscript to the editor and during his editorial processing, since it contributes to productive scientific discussion and positive impact on the efficiency and dynamics of citing published work (see. The Effect of Open Access).